Gore’s innovative peripheral arterial disease (PAD) solutions are designed to treat all stages of complex peripheral disease and backed by a body of long-term clinical data.1-5 Maintaining flow through the lower limb is one of the greatest challenges in the treatment of PAD. Our vascular family is made up of stent grafts, vascular grafts, patches and sutures.

Products Related to PAD

a As used by Gore, Heparin Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.
b Also referred to as the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface in some regions.

  1. Iida O, Ohki T, Soga Y, et al. Twelve-month outcomes from the Japanese post-market surveillance study of the Viabahn Endoprosthesis as treatment for symptomatic peripheral arterial disease in the superficial femoral arteries. Journal of Endovascular Therapy 2022;29(6):855-865.
  2. Soukas P, Becker M, Stark K, Tepe G; RELINE MAX Investigators. Three-year results of the GORE® VIABAHN® endoprosthesis in the superficial femoral artery for in-stent restenosis. Journal of the Society for Cardiovascular Angiography & Interventions 2023;2(6)Part A:101183. OPEN
    ACCESS https://www.sciencedirect.com/science/article/pii/S2772930323011857
  3. Panneton JM, Bismuth J, Gray BH, Holden A. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy 2020;27(5):728-736.
  4. Samson RH, Moreales R, Showalter DP, Lepore MR, Nair DG. Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison. Journal of Vascular Surgery 2016;64(3):638-647
  5. Kaisar J, Chen A, Cheung M, Kfoury E, Bechara C, Lin P. Comparison of propaten heparin-bonded vascular graft with distal anastomotic patch versus autogenous saphenous vein graft in tibial artery bypass. Vascular 208;26(2):117-125

25PL1135-EN01